Literature DB >> 23439566

Quinone derivatives from the rhizomes of Acorus gramineus and their biological activities.

Seung Young Lee1, Eunjung Moon, Sun Yeou Kim, Sang Un Choi, Kang Ro Lee.   

Abstract

A further phytochemical investigation of the rhizomes of Acorus gramineus afforded three new quinone derivatives (1-3), together with two known compounds (4 and 5). The identification and structural elucidation of these new compounds were based on 1D and 2D NMR (COSY, HMQC, HMBC and NOESY) and MS data. The absolute configurations were established on the basis of their circular dichroism (CD) data. To investigate the anti-neuroinflammatory effects of the isolated compounds (1-5), the nitric oxide (NO) production was evaluated in the lipopolysaccharide-activated microglia cell line, BV-2. Compounds (1-5) were also tested for their cytotoxicity against four human tumor cell lines (A549, SK-OV-3, SK-MEL-2, and HCT-15) in vitro by using the SRB assay.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23439566     DOI: 10.1271/bbb.120690

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  3 in total

1.  Antioxidant Lignans and Neolignans from Acorus tatarinowii.

Authors:  Yuanyuan Lu; Yongbo Xue; Shenjie Chen; Hucheng Zhu; Jinwen Zhang; Xiao-Nian Li; Jianping Wang; JunJun Liu; Changxing Qi; Guang Du; Yonghui Zhang
Journal:  Sci Rep       Date:  2016-03-10       Impact factor: 4.379

2.  Catalytic Synthesis of 1H-2-Benzoxocins: Cobalt(III)-Carbene Radical Approach to 8-Membered Heterocyclic Enol Ethers.

Authors:  Minghui Zhou; Lukas A Wolzak; Zirui Li; Felix J de Zwart; Simon Mathew; Bas de Bruin
Journal:  J Am Chem Soc       Date:  2021-11-21       Impact factor: 15.419

3.  Efficacy and Safety of Wei Bi Mei, a Chinese Herb Compound, as an Alternative to Bismuth for Eradication of Helicobacter pylori.

Authors:  Lei Li; FanDong Meng; Shengtao Zhu; ShuiLong Guo; YongJun Wang; Xin Zhao; YiLin Sun; Yan Zhang; QinQin Wang; HuFeng Xu; ShuTian Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-05       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.